500 related articles for article (PubMed ID: 29915586)
1. Daratumumab for the Treatment of Multiple Myeloma.
Plesner T; Krejcik J
Front Immunol; 2018; 9():1228. PubMed ID: 29915586
[TBL] [Abstract][Full Text] [Related]
2. Daratumumab: monoclonal antibody therapy to treat multiple myeloma.
Xia C; Ribeiro M; Scott S; Lonial S
Drugs Today (Barc); 2016 Oct; 52(10):551-560. PubMed ID: 27910963
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
Sherbenou DW; Mark TM; Forsberg P
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
[TBL] [Abstract][Full Text] [Related]
4. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.
van der Veer MS; de Weers M; van Kessel B; Bakker JM; Wittebol S; Parren PW; Lokhorst HM; Mutis T
Haematologica; 2011 Feb; 96(2):284-90. PubMed ID: 21109694
[TBL] [Abstract][Full Text] [Related]
5. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.
Moreau P; van de Donk NW; San Miguel J; Lokhorst H; Nahi H; Ben-Yehuda D; Cavo M; Cook G; Delforge M; Einsele H; Zweegman S; Ludwig H; Driessen C; Palumbo A; Facon T; Plesner T; Dimopoulos M; Sondergeld P; Sonneveld P; Mateos MV
Drugs; 2016 May; 76(8):853-67. PubMed ID: 27113582
[TBL] [Abstract][Full Text] [Related]
6. Daratumumab in multiple myeloma.
Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.
Nijhof IS; Groen RW; Lokhorst HM; van Kessel B; Bloem AC; van Velzen J; de Jong-Korlaar R; Yuan H; Noort WA; Klein SK; Martens AC; Doshi P; Sasser K; Mutis T; van de Donk NW
Leukemia; 2015 Oct; 29(10):2039-49. PubMed ID: 25975191
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Afifi S; Michael A; Lesokhin A
Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
[TBL] [Abstract][Full Text] [Related]
10. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Lonial S; Weiss BM; Usmani SZ; Singhal S; Chari A; Bahlis NJ; Belch A; Krishnan A; Vescio RA; Mateos MV; Mazumder A; Orlowski RZ; Sutherland HJ; Bladé J; Scott EC; Oriol A; Berdeja J; Gharibo M; Stevens DA; LeBlanc R; Sebag M; Callander N; Jakubowiak A; White D; de la Rubia J; Richardson PG; Lisby S; Feng H; Uhlar CM; Khan I; Ahmadi T; Voorhees PM
Lancet; 2016 Apr; 387(10027):1551-1560. PubMed ID: 26778538
[TBL] [Abstract][Full Text] [Related]
11. [Daratumumab for multiple myeloma].
Croizier C; Bailly S
Bull Cancer; 2018 Nov; 105(11):985-991. PubMed ID: 30430991
[TBL] [Abstract][Full Text] [Related]
12. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
[TBL] [Abstract][Full Text] [Related]
13. Emerging antibodies for the treatment of multiple myeloma.
Zagouri F; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Emerg Drugs; 2016 Jun; 21(2):225-37. PubMed ID: 27195659
[TBL] [Abstract][Full Text] [Related]
14. Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins.
Magarotto V; Salvini M; Bonello F; Bringhen S; Palumbo A
Leuk Lymphoma; 2016; 57(3):537-56. PubMed ID: 26445358
[TBL] [Abstract][Full Text] [Related]
15. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.
Sanchez L; Wang Y; Siegel DS; Wang ML
J Hematol Oncol; 2016 Jun; 9(1):51. PubMed ID: 27363983
[TBL] [Abstract][Full Text] [Related]
16. Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis.
Pick M; Vainstein V; Goldschmidt N; Lavie D; Libster D; Gural A; Grisariu S; Avni B; Ben Yehuda D; Gatt ME
Eur J Haematol; 2018 May; 100(5):494-501. PubMed ID: 29453884
[TBL] [Abstract][Full Text] [Related]
17. Daratumumab improves survival in multiple myeloma.
Baker H
Lancet Oncol; 2016 Nov; 17(11):e480. PubMed ID: 27746105
[No Abstract] [Full Text] [Related]
18. Daratumumab combination prolongs myeloma survival.
Das M
Lancet Oncol; 2016 Oct; 17(10):e422. PubMed ID: 27601427
[No Abstract] [Full Text] [Related]
19. CD38 Monoclonal Antibody Therapies for Multiple Myeloma.
Wong SW; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):635-45. PubMed ID: 26443328
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory effects of CD38-targeting antibodies.
van de Donk NWCJ
Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
